IGF-1R and IL-6R expressions in MMCs according to the molecular classification of multiple myeloma
| . | All patients . | PR . | LB . | MS . | HY . | CD1 . | CD2 . | MF . | MY . |
|---|---|---|---|---|---|---|---|---|---|
| Patient subgroups | 100 | 8.4 | 9.0 | 12.2 | 18.8 | 6.4 | 11.9 | 6 | 27.5 |
| Frequency of patients with IGF-1Rpresent | 49.9 | 75.9* | 61.3 | 92.9* | 33.8* | 22.7* | 43.9 | 55 | 37.9 |
| Frequency of patients with IL-6Rhigh | 50 | 82.8* | 93.5* | 78.6* | 38.5 | 9.1* | 17.1* | 75.0* | 39.4 |
| . | All patients . | PR . | LB . | MS . | HY . | CD1 . | CD2 . | MF . | MY . |
|---|---|---|---|---|---|---|---|---|---|
| Patient subgroups | 100 | 8.4 | 9.0 | 12.2 | 18.8 | 6.4 | 11.9 | 6 | 27.5 |
| Frequency of patients with IGF-1Rpresent | 49.9 | 75.9* | 61.3 | 92.9* | 33.8* | 22.7* | 43.9 | 55 | 37.9 |
| Frequency of patients with IL-6Rhigh | 50 | 82.8* | 93.5* | 78.6* | 38.5 | 9.1* | 17.1* | 75.0* | 39.4 |
Values are percentages. The percentage of patients with IGF-1Rpresent and IL-6Rhigh MMC was determined in the 8 patient subgroups defined by Zhan et al.3
PR indicates proliferation; LB, low bone disease; MS, MMSET; HY, hyperdiploid; CD-1 and CD-2, CCND1/CCND3; MF, MAF/MAFB; and MY, myeloid group.
The percentages of patients IGF-1Rpresent or IL-6Rhigh MMCs in a subgroup were significantly different from that in all patients with a χ2 test (P ≤ .05).